Back to top
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Bristol Myers Squibb Company (BMY) - free report >>
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Bristol Myers Squibb Company (BMY) - free report >>
Image: Bigstock
New Strong Buy Stocks for June 28th
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List today:
• Acuity Brands, Inc. (AYI - Free Report) is a producer, distributor and designer of a range of lighting solutions for commercial and residential markets across several countries. The Zacks Consensus Estimate for its current year earnings has improved by 0.2% over the last 30 days.
• Banco Bradesco S.A. (BBD - Free Report) offers a range of financial and banking services and products to individual and business customers. The Zacks Consensus Estimate for its current year earnings has improved by 3.3% over the last 30 days.
• Bristol-Myers Squibb Company (BMY - Free Report) is a global specialty biopharmaceutical company with focus on discovering, developing and delivering innovative treatments for serious diseases. It has seen the Zacks Consensus Estimate for its current year earnings climb 0.1% over the last 30 days.
• Core-Mark Holding Company, Inc. is one of the largest broad-line, full-service, wholesale distributors of packaged consumer products to the convenience retail industry in North America. It has seen the Zacks Consensus Estimate for its current year earnings climb 0.6% over the last 30 days.
• Fibrocell Science, Inc. develops first-in-class treatments for rare and serious skin and connective tissue diseases with high unmet medical needs. The Zacks Consensus Estimate revision for its current year earnings was a positive 14.2% over the last 60 days.
View the entire Zacks Rank #1 List.